Lowering the Stakes to Raise the Bar: Building an NGS Panel to Meet the Needs of Clinicians | GenomeWeb
October 27, 2016
Sponsored by
Agilent Technologies

Lowering the Stakes to Raise the Bar: Building an NGS Panel to Meet the Needs of Clinicians


Clinical Director, Center for Personalized Diagnostics, University of Pennsylvania Perelman School of Medicine

Genomics Technologist, Center for Personalized Diagnostics, University of Pennsylvania Health System

Bioinformatics Specialist
Penn Medicine, University of Pennsylvania Health System

During this webinar, speakers from the Center for Personalized Diagnostics at Penn Medicine discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.

Next-generation sequencing of tumor-derived DNA has revolutionized clinical cancer genomic diagnostics by directing molecularly targeted therapies. The accurate detection of mutations at low allele frequencies is essential for wider adoption of this approach due to high levels of stroma and tumor-infiltrating lymphocytes diluting the detectable alterations.

The Center for Personalized Diagnostics began clinical NGS of solid tumors in 2013 using a 47-gene panel covering clinically relevant genes and hotspots. This was an early success with over 3,500 solid tumors sequenced in the laboratory over three and a half years.

However, the demand to increase gene content and to detect mutations in a wider array of tumor types led the team to explore molecular barcoding to bioinformatically eliminate duplicate reads and detect variants at lower allele frequencies. The team developed a custom 153 gene Agilent HaloPlexHS NGS panel to address this need. Dr. Jennifer Morrissette and her colleague Karthik Ganapathy share details of this work and discuss key considerations for the design, technical validation, and performance of this panel. Ashkan Bigdeli, an informaticist in the CPD demonstrates that in addition to Agilent’s SureCall software, a lab can choose to write a custom script for the analysis of HaloPlexHS NGS data.

Sponsored by

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.

Sponsored by
Personal Genome Diagnostics

This webinar will discuss genomic methods to elucidate the molecular mechanisms underlying acquired resistance to immuno-oncology (IO) therapies.


This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Sponsored by
Twist BioScience

This webinar will cover methodologies for genome-wide screening with CRISPR/Cas9 in human pluripotent stem cells (hPSCs).